(NASDAQ: XENE) Xenon Pharmaceuticals's forecast annual revenue growth rate of 94.85% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Xenon Pharmaceuticals's revenue in 2025 is $7,500,000.On average, 9 Wall Street analysts forecast XENE's revenue for 2025 to be $589,242,516, with the lowest XENE revenue forecast at $578,293,493, and the highest XENE revenue forecast at $676,988,915. On average, 3 Wall Street analysts forecast XENE's revenue for 2026 to be $7,047,932,663, with the lowest XENE revenue forecast at $1,156,586,985, and the highest XENE revenue forecast at $18,059,720,242.
In 2027, XENE is forecast to generate $3,365,436,809 in revenue, with the lowest revenue forecast at $1,016,254,431 and the highest revenue forecast at $6,530,090,117.